Director of Treasury

Company Profile: Vaxcyte, Inc. (Nasdaq: PCVX) is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). The Company is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and our exclusively licensed XpressCFTM cell-free protein synthesis platform. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine program designed to prevent Shigella. The Company is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com. Vaxcyte, headquartered in San Carlos, CA, went public in June 2020 and currently has a team of approximately 180 employees and anticipates continued, significant growth. Following equity offerings in October 2022 and April 2023, which generated over $1.1 billion in net proceeds, the Company’s balance sheet is further strengthened to advance its pipeline of novel vaccines, including VAX-24. These financings followed positive data readouts from Vaxcyte’s Phase 1/2 proof-of-concept study evaluating VAX-24 in adults aged 18-64 and Phase 2 study in adults 65 and older. The Company believes these results support a best-in-class potential for VAX-24, which was designed to replace the current standard-of-care in adults and children. VAX-24 is being investigated for the prevention of IPD, which can be most serious for infants, young children, older adults and those with immune deficiencies or certain chronic health conditions. Given the global impact of pneumococcal disease remains significant, the public health community continues to advocate for vaccines that can offer broader protection to prevent IPD. Vaxcyte’s PCV franchise, consisting of VAX-24 and VAX-31, is designed specifically to address this need and has the potential to deliver the broadest protection for this very serious disease. We believe that our PCVs could receive regulatory approval based on successful completion of clinical studies utilizing well-defined surrogate immune endpoints, consistent with how other PCVs have obtained regulatory approval in the past, rather than requiring clinical field efficacy studies.  Summary: The Director of Treasury will be responsible for the ownership and leadership over all elements of our treasury management and reporting processes.  The ideal candidate is one who has strong analytical skills and financial acumen, and is driven to help the organization maximize capital, solve problems and enable growth and scaling of the organization. The candidate must have experience in various elements of the Treasury and cash management process of a sizable portfolio of investments and capital estimated at ~$2 billion in a capital-intensive business with complicated and scaling operations.  The position will be an individual contributor initially, with the capability to manage a small team or a dotted line relationship as needed to support the function.  The Director of Treasury will report to the Senior Vice President, Finance.

Essential Functions:

• Serve as the primary contact with investment advisors, commercial banks in cash management services, trust, custodians and with internal stakeholders regarding day-to-day treasury needs to ensure alignment and compliance with our policies, recommended liquidity and evaluate the appropriateness of our cash/investment strategies to optimize performance.
• Support global expansion and establishment of new entities and global banking relationships as needed.
• Develop, implement and maintain bank account structures.
• Continually optimize company’s investment portfolio.
• Develop and implement hedging programs for foreign exchange and interest-rate exposures.
• Develop reporting package for executive team and the Board of Directors on company’s liquidity and key cash management operating metrics and KPI’s.
• Evaluate internal processes to help drive operational efficiency and to ensure compliance with internal policies, controls and proc